Torray Investment Partners LLC Has $1.45 Million Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Torray Investment Partners LLC lifted its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 45.3% during the 4th quarter, HoldingsChannel reports. The fund owned 17,174 shares of the company’s stock after purchasing an additional 5,351 shares during the period. Torray Investment Partners LLC’s holdings in Axsome Therapeutics were worth $1,453,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. R Squared Ltd acquired a new stake in shares of Axsome Therapeutics during the 4th quarter valued at $64,000. KBC Group NV lifted its holdings in Axsome Therapeutics by 40.5% during the 4th quarter. KBC Group NV now owns 1,336 shares of the company’s stock worth $113,000 after buying an additional 385 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Axsome Therapeutics by 22.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company’s stock worth $156,000 after buying an additional 318 shares during the period. Moors & Cabot Inc. acquired a new position in Axsome Therapeutics during the 3rd quarter worth about $200,000. Finally, Whalen Wealth Management Inc. acquired a new position in Axsome Therapeutics during the 3rd quarter worth about $236,000. Institutional investors and hedge funds own 81.49% of the company’s stock.

Axsome Therapeutics Stock Performance

Shares of Axsome Therapeutics stock opened at $127.15 on Tuesday. Axsome Therapeutics, Inc. has a one year low of $64.11 and a one year high of $139.13. The firm has a market capitalization of $6.20 billion, a price-to-earnings ratio of -21.23 and a beta of 1.05. The business has a 50-day simple moving average of $105.81 and a 200 day simple moving average of $96.81. The company has a debt-to-equity ratio of 3.22, a current ratio of 2.11 and a quick ratio of 2.04.

Axsome Therapeutics (NASDAQ:AXSM) last issued its earnings results on Tuesday, February 18th. The company reported ($0.96) EPS for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.01. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. The business had revenue of $118.77 million during the quarter, compared to analyst estimates of $117.83 million. On average, research analysts anticipate that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. HC Wainwright lifted their target price on Axsome Therapeutics from $190.00 to $200.00 and gave the stock a “buy” rating in a report on Thursday, February 20th. William Blair reaffirmed an “outperform” rating on shares of Axsome Therapeutics in a report on Tuesday, February 18th. Wells Fargo & Company lifted their target price on Axsome Therapeutics from $140.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. Royal Bank of Canada lifted their target price on Axsome Therapeutics from $143.00 to $192.00 and gave the stock an “outperform” rating in a report on Wednesday, February 19th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $153.00 price objective on shares of Axsome Therapeutics in a research report on Wednesday, February 19th. One investment analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $167.36.

Insider Activity at Axsome Therapeutics

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $131.07, for a total transaction of $393,210.00. Following the completion of the sale, the chief financial officer now directly owns 42,187 shares of the company’s stock, valued at approximately $5,529,450.09. The trade was a 6.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 22.40% of the stock is currently owned by corporate insiders.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.